Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02167945 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 615
- Enrollment target
NCT02167945: Completed Phase 3 study, sponsored by AbbVie.
NCT02167945 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 615 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02167945, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 615 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the effect of treatment with ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333; 3-DAA regimen, with or without ribavirin (RBV) in adults with chronic hepatitis C virus genotype 1 (HCV GT1) infection.
Primary Outcome
Time to all-cause death was defined as the number of days from the first day of study drug dosing for the participant to the date of death. All deaths were to be included, regardless of whether the death occurred while the participant was still taking study drug or had previously discontinued study drug. If the participant did not die, their data was to be censored at the date of their last available assessment of clinical outcomes. For participants with no post-baseline assessment, the particip
Interventions
- DRUG Ribavirin (RBV)
- DRUG ABT-333
- DRUG ABT-450/r/ABT-267
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 615 participants |
| Start Date | 2014-06-12 |
| Est. Completion | 2021-05-13 |
| Phase | Phase 3 |
What the finished NCT02167945 record still lists
NCT02167945 is an interventional study that assigns participants to a tested intervention. The registered 615 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 3 interventions - of which Ribavirin (RBV) is the first listed.
NCT02167945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02167945 about?
NCT02167945 is a clinical study titled "A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection". The purpose of this study was to evaluate the effect of treatment with ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333; 3-DAA regimen, with or without ribavirin (RBV) in adults with chronic hepatitis C virus genotype 1 (HCV GT1) infection.
What is the current status of trial NCT02167945?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 615 participants. The study started on 2014-06-12. Estimated completion is 2021-05-13.
What interventions are being tested in trial NCT02167945?
The interventions under investigation include: Ribavirin (RBV) (DRUG), ABT-333 (DRUG), ABT-450/r/ABT-267 (DRUG).
Who is sponsoring clinical trial NCT02167945?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02167945's enrollment target sits among peer trials
615 593rd of 2000 higher than 1,408 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06593652 · 615 participants · NA
Evaluating Caregiver Involvement in Primary Care-Based Brief Interventions for Adolescent Alcohol Use Problems
- NCT04813185 · 616 participants · NA
Preventing Retaliatory Gun Violence in Violently Injured Adults
- NCT06105957 · 616 participants · NA
Optimal Digital Weight Loss Treatment for Rural Individuals
- NCT06162221 · 616 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI